EPIRUS Biopharmaceuticals, Inc. (NASDAQ:EPRS) initiated the shares trading at $0.1000 and showed negative change of -22.2500% while the stock’s final trade was registered at $ 0.0933. However, its previous closing price was seen at $0.1200. The stock negotiated total number of 5.13 million shares as compared to 3 months average volume of 1.84 million shares.
The stock price demonstrated downbeat change from its 50 day moving average of 0.4263 and had been down from its 200 Day Moving Average of 1.9440.
EPIRUS Biopharmaceuticals, Inc.’s (EPRS) has price-to-cash ratio of 0.17 and price to sale ratio of 2.32. The company gross profit margin is 91.50%. A look on the firm performance, its monthly performance is -77.91% and a quarterly performance of -96.21%. The stock price is moving down from its 20 days moving average with -71.18% and isolated negatively from 50 days moving average with -81.08%.
Shares of Becton, Dickinson and Company (NYSE:BDX) climbed +1.30% and ended at $175.03 greater than previous closing price of $172.78. The total 780.75 thousand shares were bought and sold throughout the most recent trading session less than average volume of 931.34 thousand shares.
The average true range of Becton, Dickinson and Company’s (BDX) is recorded at 2.34 and the relative strength index of the stock stands 58.28. The stock price is going above to its 52 week low with 37.55% and lagging behind from its 52 week high with -1.39%. Analyst recommendation for this stock stands at 2.00. A look on the firm performance, its monthly performance is 0.34% and a quarterly performance of 8.23%. The stock price is trading upbeat from its 200 days moving average with 13.94% and up from 50 days moving average with 3.30%.
According to ZACKS data, different Brokerage Firms rated the stock about their BUY, SELL or HOLD recommendations. One week ago, shares have been suggested as “BUY” from “5” brokerage firms and recommended as “Strong Buy” by “0” brokerage firms. 0” brokerage firms have issued “Sell” rating for the company and “Strong Sell” rating was issued by “1.71” brokerage firms. “0” brokerage firms have rated the company as a “Hold”. The Corporation has average brokerage recommendation (ABR) of 0 based on consensus of the brokerage firms issuing ratings.